Search

everythinglearnresearchcommunity

for

Search:↓

Female considering adding topical anti-androgen, seeks advice on RU58841 or pyrilutamid's binding affinity compared to spironolactone.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. User asks if RU58841 powder mixed in stemoxydine needs refrigeration and if it maintains quality at room temperature like pre-mixed solutions.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

The user applies a topical solution containing minoxidil, finasteride, dutasteride, retinoic acid, and hydrocortisone to address scalp inflammation and is considering adding cetirizine to the mix. They are calculating the correct amount of cetirizine to add to their formula and have paused this approach to retry oral minoxidil.

The conversation discusses various theories of hair loss, including DHT sensitivity and genetic factors, with the user willing to use themselves for research due to having a hair loss gene but different hair loss patterns compared to their brothers. Specific treatments were not mentioned in the provided text.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

The post discusses a user's 2-month progress in treating hair loss using topical Du once a week, microneedling, and red light therapy. The user notes that red light therapy is primarily for face and body inflammation but also applies it to the scalp.

KX-826 users report increased shedding, with some experiencing more shedding at higher concentrations. Users are discussing where to purchase the product.

The conversation is about which blood tests to get for hair loss treatment, besides Vitamin D. No specific treatments were mentioned.

The conversation is about a user experiencing hair shedding after using a brand of RU58841, questioning its effectiveness and safety. Concerns are raised about RU58841 being an abandoned research chemical and the use of heavy oils like castor and argan oil potentially affecting absorption.

OP mixed RU58841 with minoxidil and initially saw crystals, but realized they were bubbles. They asked for advice on application frequency for a 5% solution.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.

User shares a topical hair loss solution using melatonin and cetirizine to help reduce shedding and itching. Instructions provided for creating and using the mixture, with additional lifestyle tips for overall hair health.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

User shares link to conference about Pyrilutamide. Discussion includes phase 2 results, company's plans, and upcoming phase 3 trial.

Pyrilutamide, a new hair loss product with the potential to be more effective than RU58841 and safer than CB, but expensive.

The conversation is about making a topical solution from clascoterone powder, with references to using a RU58841 mixing guide for guidance. Concerns about product authenticity and bulk purchase requirements are also discussed.

The conclusion of the conversation is that the user has experienced significant hair regrowth using a mixture of oils, including rosemary essential oil, peppermint essential oil, and carrier oils like castor oil or jojoba oil. The user also clarifies that both pictures were taken with damp hair.

The post and conversation are about HMI-115, a potential treatment for hair loss. The conclusion is that HMI-115 is not a 5ar-inhibitor and is instead a prolactin receptor inhibitor. Some users are skeptical about its effectiveness and believe that baldness will still be a problem in the future.

Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.

Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).

The user experiences an itchy scalp and finds relief using shampoo and Zyrtec, which helps with inflammation. They are unsure if the issue is related to histamines or seborrheic dermatitis.

A user seeks a minoxidil and tretinoin foam-based product for improving a patchy beard in India. They are unsure about the safety of alcohol-based options for beard use.

A user with diffuse thinning shares a tip for improving hair appearance by using a shea butter and coconut oil serum from Trader Joe's at night. They are on finasteride and considering adding minoxidil for better results.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. Update on HMI-115 clinical trial expected in July or August.

The conversation discusses using minoxidil with retinol for hair loss treatment. Users share their experiences and opinions on the effectiveness of this combination.

RU58841 helped reduce scalp itching for some users within a week, while others experienced immediate relief. Some users reported initial irritation from the solution, possibly due to the carrier used.

Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.

The conversation discusses a user's unconventional hair loss treatment involving scalp massage, dermastamping, and pouring hot water to induce a burning sensation, with a warning not to try it without further evidence. Other users suggest more traditional treatments like Minoxidil and finasteride, while expressing skepticism and concern about the hot water method.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.